BlackBarn Capital Partners LP holds a focused book of 17 reported positions worth $402.2M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Unitedhealth Group Inc and trimmed Roivant Sciences Ltd. Their largest long position is Roivant Sciences Ltd at 18% of the reported non-option book. They also disclosed $698.4M in put options (a bearish bet) and $84.7M in call options (bullish), shown separately below and excluded from the non-option book. Cloning the disclosed picks since 2024 would be +78% (+25.2%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +96.6%, a 18.3-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning BlackBarn Capital Partners LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as BlackBarn Capital Partners LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Sourcerock Group LLC | 3 / 17 | $371.4M |
| Bayban | 2 / 17 | $17.1M |
| Penn Davis McFarland Inc | 2 / 17 | $112.6M |
| Asset Management Advisors, LLC | 2 / 17 | $15.8M |
| Edgar Lomax Co | 2 / 17 | $114.1M |
| Scharf Investments, LLC | 2 / 17 | $233.7M |
| Slocum, Gordon & Co LLP | 2 / 17 | $10.5M |
| ADAR1 Capital Management, LLC | 4 / 17 | $114.0M |
Ranked by the share of each fund's own book sitting in the names it shares with BlackBarn Capital Partners LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd SHS | $70.8M | 2.00M | 17.6% | ▼−12% Reduced · −285K sh | |
| 2 | Privia Health Group Inc COM | $40.8M | 1.58M | 10.1% | —Held | |
| 3 | Diversified Healthcare TR COM SH BEN INT | $37.9M | 4.08M | 9.4% | ▼−15% Reduced · −737K sh | |
| 4 | NextEra Energy Inc COM | $29.4M | 335.0K | 7.3% | —Held | |
| 5 | Niq Global Intelligence PLC ORDINARY SHARES | $27.2M | 2.90M | 6.8% | ▲+40% Added · +829K sh | |
| 6 | Unitedhealth Group Inc COM | $27.0M | 65.0K | 6.7% | ▲New New position | |
| 7 | NXP Semiconductors N V COM | $25.3M | 90.0K | 6.3% | ▲+50% Added · +30K sh | |
| 8 | Viking Therapeutics Inc COM | $23.4M | 600.0K | 5.8% | ▼−3.5% Reduced · −21K sh | |
| 9 | McGraw Hill Inc COM | $23.2M | 2.45M | 5.8% | ▲+17% Added · +362K sh | |
| 10 | Amneal Pharmaceuticals Inc COM STK CL A | $22.5M | 1.30M | 5.6% | ▼−21% Reduced · −350K sh | |
| 11 | Venture Global Inc COM CL A | $19.5M | 1.75M | 4.8% | ▲New New position | |
| 12 | Azul S A SPONSORED ADS | $15.1M | 1.68M | 3.8% | ▲New New position | |
| 13 | Occidental Pete Corp COM | $12.1M | 250.0K | 3.0% | ▲New New position | |
| 14 | Arbutus Biopharma Corp COM | $12.0M | 2.50M | 3.0% | —Held | |
| 15 | California Res Corp COM STOCK | $9.3M | 175.0K | 2.3% | ▲New New position | |
| 16 | Cogent Communications Hldgs COM NEW | $3.5M | 250.0K | 0.9% | ▼−50% Reduced · −250K sh | |
| 17 | Vivid Seats Inc COM CL A | $3.3M | 500.0K | 0.8% | —Held |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2010204/holdings"
Use Arkolith to show BlackBarn Capital Partners LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $597.4M | 800K |
| PUT · bearish | OSCAR HEALTH INC - CLASS AOSCR | $49.9M | 1.8M |
| CALL · bullish | UNITEDHEALTH GROUP INCUNH | $41.6M | 100K |
| PUT · bearish | RESMED INCRMD | $39.0M | 200K |
| CALL · bullish | VENTURE GLOBAL INC-CL AVG | $33.4M | 3.0M |
| PUT · bearish | WARBY PARKER INC-CLASS AWRBY | $12.1M | 400K |
| CALL · bullish | VIKING THERAPEUTICS INCVKTX | $9.8M | 250K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the non-option book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 24 | $1.2B | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 21 | $1.2B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 16 | $1.5B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 20 | $1.4B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 23 | $1.7B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 44d | 22 | $1.6B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 17 | $1.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 20 | $761.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 21 | $1.1B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 23 | $176.9M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 22 | $276.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.